

Publication	Date	Reporter
Pharmabiz	25/10/2018	Staff Reporter

Syngene International net up by 1.7% in Q2

Syngene International, engaged in providing contract research and manufacturing services belonging to Biocon, has posted marginal growth in net profit during the second quarter ended September 2018. Its net profit increased only by 1.7 per cent to Rs. 78.2 crore from Rs. 76.9 crore in the corresponding period of last year. Its sales increased by 24.8 per cent to Rs. 418.6 crore from Rs. 335.2 crore. EPS worked out to Rs. 3.95 as against Rs. 3.88 in the last period.

Jonathan Hunt, CEO, said, "We are happy to report sustained growth in the second quarter with revenue up 24 percent to Rs. 437 crore. Both our Discovery Services and Dedicated Centre verticals performed well, with the later benefiting from expansions announced earlier in the year of our collaboration with Baxter. Overall, we are making good progress on our strategic plan; margins for the quarter reflect our ongoing investments in safety, quality and expanded sales and marketing, which are already starting to deliver operational benefits, and look forward to maintaining momentum through the year."

For the first half ended September 2018, Syngene's net sales increased by 31.7 per cent to Rs. 825 crore from Rs. 626 crore in the similar period of last year. Its net profit increased only by 3.8 per cent to Rs 144.2 crore from Rs. 138.9 crore. EBITDA improved by 12 per cent to Rs. 273 crore from Rs. 243 crore and EBITDA margins worked out to 32 per cent as against 37 per cent in the last period.

With marginal growth in profits, Syngene scrip declined by Rs. 15.50 to Rs. 570 in the afternoon today on BSE from its previous day's close of Rs. 585.50.

Source: <http://www.pharmabiz.com/NewsDetails.aspx?aid=111917&sid=2>